AHA: AstraZeneca’s Farxiga outcomes data looks even better in patients without diabetes – FiercePharma

Seems AstraZeneca’s “paradigm racy” outcomes files for SLGT2 med Farxiga observe an even elevated cardiovascular earnings for sufferers who accomplish no longer own diabetes than those that make—and this for a drug designed specifically to treat the disease.
Read More